콘텐츠로 건너뛰기
Merck

PHR1043

Supelco

Prednisolone

Pharmaceutical Secondary Standard; Certified Reference Material

동의어(들):

1,4-Pregnadiene-11β,17α,21-triol-3,20-dione, 1-Dehydrocortisol, 1-Dehydrohydrocortisone, 11β,17α,21-Trihydroxy-1,4-pregnadiene-3,20-dione

로그인조직 및 계약 가격 보기

크기 선택

제품정보 (DICE 배송 시 비용 별도)

실험식(Hill 표기법):
C21H28O5
CAS 번호:
50-24-8
Molecular Weight:
360.44
Beilstein:
1354103
EC Number:
200-021-7
MDL number:
MFCD00003649
UNSPSC 코드:
41116107
PubChem Substance ID:
329823073
NACRES:
NA.24

주요 문서

모든 문서 보기
기술 서비스
도움이 필요하신가요? 저희 숙련된 과학자 팀이 도와드리겠습니다.
도움 문의
기술 서비스
도움이 필요하신가요? 저희 숙련된 과학자 팀이 도와드리겠습니다.
도움 문의

Grade

certified reference material
pharmaceutical secondary standard

Quality Level

300

Agency

traceable to Ph. Eur. P2700000
traceable to USP 1555005

API family

prednisolone

CofA

current certificate can be downloaded

포장

pkg of 500 mg

기술

HPLC: suitable
gas chromatography (GC): suitable

mp

240 °C (dec.) (lit.)

응용 분야

pharmaceutical (small molecule)

형식

neat

저장 온도

2-30°C

SMILES string

O=C1C=C[C@@]2(C)C(CC[C@]3([H])[C@]2([H])[C@@H](O)C[C@@]4(C)[C@@]3([H])CC[C@]4(O)C(CO)=O)=C1

InChI

1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1

InChI key

OIGNJSKKLXVSLS-VWUMJDOOSA-N

유전자 정보

human ... NR3C1(2908)

유사한 제품을 찾으십니까? 방문 제품 비교 안내

관련 카테고리

일반 설명

Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Prednisolone is a glucocorticoid utilized as an anti-inflammatory or an immunosuppressive drug.

애플리케이션

Prednisolone may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical formulations by chromatography techniques.
Prednisolone may be used as a standard in the separation and determination of prednisolone in serum samples of animals using radioimmunoassay.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

분석 메모

These secondary standards offer multi-traceability to the USP and EP (PhEur) primary standards, where they are available.

기타 정보

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.
To see an example of a Certificate of Analysis for this material enter LRAA6903 in the slot below. This is an example certificate only and may not be the lot that you receive.

픽토그램

Health hazard
GHS08

신호어

Danger

유해 및 위험 성명서

H360FD

Hazard Classifications

Repr. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Development and validation of spectrophotometric and HPLC method for the simultaneous estimation of salbutamol sulphate and prednisolone in tablet dosage form
Chitlange SS, et al.
Journal of Analytical and Bioanalytical Techniques, 2(117), 2-2 (2011)
Separation of serum prednisolone and prednisolone-21-hemisuccinate by extraction and their concurrent determination by radioimmunoassay
Yanaglbashl, K, et al.
Clinical Chemistry, 26(9), 1301-1303 (1980)
Quantitative determination of captopril and prednisolone in tablets by FT-Raman spectroscopy
Mazurek S and Szostak R
Journal of Pharmaceutical and Biomedical Analysis, 40(5), 1225-1230 (2006)
Vappu Rantalaiho et al.
Annals of the rheumatic diseases, 73(11), 1954-1961 (2013-08-03)
To study whether adding initial infliximab to remission-targeted initial combination-DMARD treatment improves the long-term outcomes in patients with early rheumatoid arthritis (RA). Ninety-nine patients with early, DMARD-naïve RA were treated with a triple combination of DMARDs, starting with methotrexate (max
J A P Spijkers-Hagelstein et al.
Leukemia, 28(4), 761-769 (2013-08-21)
Successful treatment results for MLL-rearranged Acute Lymphoblastic Leukemia (ALL) in infants remain difficult to achieve. Significantly contributing to therapy failure is poor response to glucocorticoids (GCs), like prednisone. Thus, overcoming resistance to these drugs may be a crucial step towards
모든 관련된 서류 보기

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.